Navigation Links
Baltimore to Host Largest Gathering of Cystic Fibrosis Scientists and Clinicians in the World
Date:10/19/2010

BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 –23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care.

The conference comes at a critical point in the history of cystic fibrosis, a fatal genetic disease that causes life-threatening lung infections and premature death. For the first time, drugs that treat the underlying cause of the disease have reached the final stages of clinical testing. Up to now, only drugs that treat the symptoms of CF have been available to patients. Therapies in Phase 3 include: ataluren, Bronchitol, denufosol, and VX-770.

Key topics of the conference include:

  • Attacking the core defect in CF from every angle;
  • The power of patient and family involvement in improving care;
  • Grappling with adult issues as people with CF live increasingly longer; and
  • Advancements in inhaled antibiotics for CF.

An estimated 30,000 people in the United States have cystic fibrosis, and about 70,000 people worldwide. Ten million Americans are unknowing carriers of a defective CF gene. Fifty years ago, most children with CF died before reaching kindergarten. Today, because of Cystic Fibrosis Foundation-supported drug research and care, people with CF are living into their 30s, 40s and beyond.

WHAT:

The 24th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.

WHEN & WHERE:

Thursday, Oct. 21 - Saturday, Oct. 23, 2010, at the Baltimore Convention Center, Baltimore, Maryland

KEYNOTE SPEAKERS:

  • Thurs., Oct. 21 at 4:20 p.m. – "Pipeline: Airway Surface Liquid Modulation'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
10. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
11. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NASDAQ: QCOR ) today announced ... to its Board of Directors.  Dr. Whitcup is ... Chief Scientific Officer at Allergan, Inc.  In that ... research and development organization, including medical affairs, drug ...
... Feb. 16, 2012 OPKO Health, Inc. and ChromaDex ... a strategic alliance pursuant to which ChromaDex has licensed ... health care technologies for distribution and business development throughout ... commercialized are BluScience™ ( www.bluscience.com ), ChromaDex,s ...
Cached Medicine Technology:Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 2Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 3Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 4OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... (Nasdaq: DIET ), a leading provider of convenient ... for the third,quarter and nine months ended September 30, ... were $4.8 million, compared to,$6.8 million in the prior ... or $(0.13) per diluted share, for the third quarter ...
... of successful pregnancy, research suggests , , THURSDAY, Nov. 13 ... to harden plastic packaging for many foods and beverages, ... (BPA) could hurt the chances of successful in vitro ... the uterus, according to presentations at the American Society ...
... 13 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced that the New ... formulation,of Trelstar(R) (triptorelin pamoate) has been accepted ... and Drug Administration (FDA). Trelstar(R) is a,luteinizing ...
... Alaska,s alcohol tax increases tied to a drop in cirrhosis, ... Raising state taxes on alcohol may trigger an immediate drop ... new research reveals. , The finding is based on the ... to raise taxes on beer, wine and liquor in 1983 ...
... g has been approved by the U.S. Food and Drug Administration ... dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual ... , ... COLLEGEVILLE, Pa. (Business Wire EON) November 13, 2008 ...
... The American Veterinary,Medical Association (AVMA) hand delivered ... Barack Obama, congratulating him on his historic,election to ... and,animal-related issues on which the AVMA is prepared ... to President-elect Obama, signed by AVMA Chief Executive,Officer ...
Cached Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Chemical in Plastics May Cause Fertility Problems 2Health News:Chemical in Plastics May Cause Fertility Problems 3Health News:Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer 2Health News:Booze Taxes Lower Alcohol-Linked Deaths 2Health News:Booze Taxes Lower Alcohol-Linked Deaths 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4Health News:AVMA Congratulates President-Elect Obama, Highlights Key Issues 2
... can code the charge while completing a chart ... away from office, both directly feeding the charge ... Encounter Form/Superbill, data entry can be done with ... payments are posted by reflecting open item charges, ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... that a second mirror adds, then you may ... features the same 1.5x magnification as the G-1 ... and 64 respectively. Available in standard (flange) or ... "Flanged" model for laser use. Provides ...
... The AFX (Air Fluid ... image lens designed for use ... addition to its use as ... lens, the low profile and ...
Medicine Products: